Parisian biotech AAVLife has come out of stealth with a Versant Ventures-led $12 million A round, looking to advance a gene-deleting therapy that promises to treat the rare and deadly Friedreich’s ataxia.

…read more

Source: Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy


0 No comments